Contents
The share price of Indivior has been on a roller coaster ride in recent years. The stock was trading at over $30 per share in early 2014, but plunged to less than $5 per share by the end of that year. It then recovered somewhat in 2015 and 2016, but has fallen back below $10 per share in 2017.
Given the company’s large debt load and challenging business environment, it is not surprising that the stock has been so volatile. However, investors may be wondering if the current share price provides an attractive entry point.
Indivior is a pharmaceutical company that specializes in the treatment of addiction and mental health disorders. The company’s share price has been on a roller coaster ride in recent years, but has stabilised somewhat in the past few months.
The company has been under pressure due to regulatory issues and Generic competition, but the recent launch of its new product SUBLOCADE has given it a boost.
Indivior is now looking to rebound and investors are waiting to see if the company can deliver on its promises.
Three AIM stocks we own and two we have avoided
Indivior News
Indivior is a global pharmaceutical company that specializes in the development and commercialization of products for the treatment of opioid dependence and other mental health disorders. The company’s portfolio includes Suboxone, an FDA-approved medication for the treatment of opioid dependence, as well as a number of other products in various stages of development.
In recent news, Indivior has announced that it has entered into a definitive agreement to sell its U.S. rights to Suboxone Film to VIVITROL Pharmaceuticals Inc., a subsidiary of Alkermes plc, for $265 million.
This follows Indivior’s announcement last month that it would be exploring strategic alternatives for its U.S. business, including a potential sale or spin-off.
The sale of Suboxone Film is subject to customary closing conditions, including antitrust clearance in the United States, and is expected to close in the second half of 2019. Following the completion of the sale, Indivior will retain all rights to Suboxone outside of the United States and will continue to manufacture and supply Suboxone Film for use in VIVITROL’s commercialization efforts in the United States under an exclusive supply agreement with Alkermes plc.
Credit: www.fiercebiotech.com
Indivior’s share price is currently trading at $0.93, down from its 52-week high of $32.38. The company has been struggling in recent years, due to declining sales of its flagship product Suboxone Film, which is used to treat opioid addiction. In 2019, the company was hit with a $600 million fine from the U.S. Department of Justice for allegedly misleading doctors and patients about the risks of using Suboxone Film.
Indivior has also been facing competition from generic versions of Suboxone Film. As a result of these challenges, Indivior’s share price has fallen sharply in recent years.
Indivior’s share price has been on a roller coaster ride over the past few years. The stock hit a 52-week high of $35.88 in February 2018 and then plunged to a 52-week low of $2.88 in December 2018. Indivior recovered some lost ground in 2019, but the stock is still down more than 90% from its 2018 highs.
The company has been plagued by legal troubles related to its flagship product, Suboxone Film, which is used to treat opioid addiction. In April 2019, Indivior was hit with a $1 billion fine by the U.S. Department of Justice for allegedly misleading doctors and patients about the risks associated with Suboxone Film.
Indivior has also been facing generic competition for Suboxone Film since early 2019, which has weighed heavily on the company’s financial performance.
In response to the challenges it is facing, Indivior has been cutting costs and divesting non-core assets.
Despite all of the headwinds it is facing, Indivior remains committed to its mission of helping people overcome addiction and rebuild their lives.
Share prices fluctuate for a variety of reasons, but the most common reason is changes in supply and demand. When more people are interested in buying a stock, the price goes up. When more people are selling, the price goes down.
Other factors that can affect share prices include earnings reports, analyst recommendations, and economic news.
When it comes to determining share prices, there are a number of different factors that can come into play. For publicly traded companies, the stock market is where shares are bought and sold – and the price is determined by the forces of supply and demand. But what can affect these forces?
One major factor is earnings announcements. If a company reports strong earnings for a quarter, this can lead to an increase in demand (and therefore price) for its stock. On the other hand, if a company misses earnings expectations, this can lead to a sell-off as investors lose confidence.
Other important factors include economic indicators, such as gross domestic product (GDP) growth or inflation rates, as well as political instability or natural disasters. These can all lead to changes in investor sentiment, which in turn affects share prices.
Another key driver of share prices is valuation ratios – specifically, the price-to-earnings (P/E) ratio.
This measures how much investors are willing to pay for each dollar of a company’s earnings, and is used to determine whether a stock is undervalued or overvalued. A high P/E ratio means that investors are expecting strong future growth and are willing to pay more for the stock today; conversely, a low P/E ratio indicates that they believe the current share price is too high relative to earnings potential.
To sum up, there are many different factors that can affect share prices – from quarterly results to global events – so it’s important to keep tabs on all of them if you want to make informed investment decisions.
Conclusion
Indivior is a pharmaceutical company that specializes in addiction treatment. The company’s share price has been on a bit of a roller coaster ride lately, but it looks like things may be stabilizing. Despite some challenges, Indivior still has a strong product portfolio and solid financials.
With the global market for addiction treatment expected to grow, Indivior looks like it could be a good long-term investment.
